Amendment to Regulation (EU) 2017/1001 (+2 more)
This procedure concerns the creation of a unitary supplementary certificate for medicinal products. It aims to simplify and strengthen the intellectual property framework for pharmaceuticals within the EU, potentially encouraging innovation and faster access to new treatments.
The proposal updates existing regulations on European patents, community patents, and industrial property. It affects pharmaceutical companies, researchers, and potentially patients by influencing the availability and cost of medicines.
Documents
Amendment to Regulation (EU) 2017/1001 (+2 more)
position · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
proposal · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
report · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
report · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
proposal · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
proposal · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
report · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
proposal · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
report · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
proposal · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
report · EN · 2026-05-02
Amendment to Regulation (EU) 2017/1001 (+2 more)
report · EN · 2026-05-02
